Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05002127 · ClinicalTrials.gov registry record · Phase 2

A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)

A Phase 2 study of Gastric Cancer and Gastric Adenocarcinoma, sponsored by ALX Oncology.

Active
Registry status
Phase 2
Development phase
127
Enrollment target
20
Study locations

NCT05002127 is a Phase 2 study of Gastric Cancer and Gastric Adenocarcinoma that is active but no longer recruiting, run by ALX Oncology. The registered enrollment target is 127 participants, below the 318-participant average among 153 other Gastric Cancer trials with a reported enrollment target (60% lower). The trial reports 20 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05002127, a Phase 2 study of Gastric Cancer and Gastric Adenocarcinoma, is active but no longer recruiting, sponsored by ALX Oncology.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
127 participants
Enrollment target
20
Study locations

Study Summary

A Phase 2/3 Study of Evorpacept (ALX148) in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Patients With Advanced HER2-overexpressing gastric/GEJ adenocarcinoma.

Conditions Studied

Gastric Cancer Gastric Adenocarcinoma Gastroesophageal Junction Adenocarcinoma

Interventions

  • DRUG Trastuzumab
  • DRUG Paclitaxel
  • DRUG Evorpacept (ALX148)
  • DRUG Ramucirumab

Study Locations (20)

Other

  • Universitair Ziekenhuis Antwerpen - Antwerp
  • Universitair Ziekenhuis Leuven - Campus Gasthuisberg - Leuven
  • Centre Hospitalier Universitaire de Liège - Liège
  • Fakultní Nemocnice Hradec Králové - Hradec Králové
  • Fakultní Nemocnice Olomouc - Olomouc
  • Vseobecna Fakultni Nemocnice v Praze - Prague
  • Centre Hospitalier Régional et Universitaire de Besançon - Hôpital Jean-Minjoz - Besançon
  • Centre Hospitalier Universitaire de Bordeaux - Bordeaux
  • Hôpital Morvan - Brest
  • Centre Léon Bérard - Lyon
  • Hôpital Privé Jean Mermoz - Lyon
  • Institut Paoli-Calmettes - Marseille
  • Hôpital Saint-Antoine - Paris

California

  • The Oncology Institute of Hope & Innovation - Anaheim
  • University of California Los Angeles - Los Angeles

Tennessee

  • Vanderbilt University Medical Center - Nashville

Virginia

  • NEXT Virginia - Fairfax

Washington

  • Fred Hutchinson Cancer Center - Seattle

Queensland

  • Icon Cancer Centre Southport - Southport

Victoria

  • Monash Medical Centre - Clayton

Trial Details

FieldValue
Enrollment Target 127 participants
Start Date 2022-01-15
Est. Completion 2026-06
Phase Phase 2

Sponsor

ALX Oncology

9 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05002127

The ClinicalTrials.gov registry entry for NCT05002127 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 127 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 318-participant average among 153 other Gastric Cancer trials with a reported enrollment target (60% lower). The listed sponsor is ALX Oncology, which has 9 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Gastric Cancer appearing as the primary indexed condition, and to 4 interventions - of which Trastuzumab is the first listed.

NCT05002127 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Other, California, Tennessee.

Frequently Asked Questions

What is clinical trial NCT05002127 about?

NCT05002127 is a clinical study titled "A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)". A Phase 2/3 Study of Evorpacept (ALX148) in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Patients With Advanced HER2-overexpressing gastric/GEJ adenocarcinoma.

What is the current status of trial NCT05002127?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 127 participants. The study started on 2022-01-15. Estimated completion is 2026-06.

What conditions does trial NCT05002127 study?

This clinical trial studies the following conditions: Gastric Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma.

What interventions are being tested in trial NCT05002127?

The interventions under investigation include: Trastuzumab (DRUG), Paclitaxel (DRUG), Evorpacept (ALX148) (DRUG), Ramucirumab (DRUG).

Who is sponsoring clinical trial NCT05002127?

This trial is sponsored by ALX Oncology, which has 9 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05002127 being conducted?

This trial has 20 study locations across California, Tennessee, Virginia, Washington, Queensland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Gastric Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Gastric Cancer

All registered trials for this condition

Gastric Adenocarcinoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.